Novavax, Inc. (NASDAQ:NVAX) does about 7.60M shares in volume on a normal day but saw 5296213 shares change hands in Monday trading. The company now has a market cap of 576.59M USD. Its current market price is $4.12, marking a decrease of -3.74% compared to the previous close of $4.28. The 52 week high reached by this stock is $11.36 whilst the lowest price level in 52 weeks is $3.53.
Novavax, Inc. (NVAX) has a 20-day trading average at $4.59 and the current price is -63.73% off the 52-week high compared with 16.63% distance from its 52-week low. The 50-day simple moving average of the closing price is $4.67 and its 200-day simple moving average is $6.18. If we look at the stock’s price movements over the week, volatility stands at 5.14%, which increases to 5.39% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 34.70 to suggest the stock is neutral.
The consensus objective for the share price is $15.40, suggesting that the stock has a potential upside of 73.25% over the period.
The company shares received a number of brokerage firm price updates over the past month, with the latest being on August 09, 2023 when B. Riley Securities upgraded the stock to “Buy” and issued a price target of $15. TD Cowen downgraded the stock to “Market Perform” from Outperform on April 20, 2023 at a price target of $55-$10. B. Riley Securities downgraded its price target at $29-$10.
Novavax, Inc. (NVAX) stock is down -7.00% over the week and -17.27% over the past month. Its price is -14.17% year-to-date and -56.72% over the past year.
The stock last released its quarterly earnings report for quarter ended 12/31/2023, with the company’s earnings per share (EPS) of -$1.44 below consensus estimates by -$0.99. NVAX’s earnings per share are forecast to grow by 86.50% this year and 93.20% over next year. Expected sales for next quarter are $76.65 million, which analysts say will come at $849.66 million for the current fiscal year and next year at $986.48 million. In addition, estimates put the company’s current quarterly revenue at an average of $101.45 million.
To reach the target analysts have set, the stock logically needs to grow 73.25 percent from here.
The beta has a value of 1.62. Price to sales ratio is 0.59.
